** Shares of drug developer Revolution Medicines RVMD.O up 7.7% to $53.51 premarket

** U.S. FDA announced nine products, including RVMD's daraxonrasib for pancreatic cancer, under new fast-track review process

** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months

** Brokerage Oppenheimer thinks daraxonrasib's first approval could come as early as mid-2026

** Eli Lilly's LLY.N experimental weight-loss pill, orforglipron, was expected to be included in the list

** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered

** LLY shares down 4.2% premarket

** YTD, up to last close, RVMD up 13.6% vs LLY's 6.1% rise

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))